Mylan has agreed to purchase the global marketing rights of GA Depot from Mapi Pharma.

Mylan will invest $20m in Mapi Pharma, as part of the transaction.

Both companies will collaborate on the development and commercialisation of GA Depot, an injectable formulation used for the treatment of multiple sclerosis.

Based in the UK, Mylan is a pharmaceutical company, while Mapi Pharma is a clinical-stage pharmaceutical company based in Israel.

Italian pharmaceutical company Recordati has purchased the rights to Cystagon (cysteamine bitartrate) in Europe from Mylan.

Cystagon is indicated for the treatment of nephropathic cystinosis in children and adults.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based in the UK, Mylan is both a generic and specialist pharmaceutical company.

Pharmaceutical company Mylan has issued senior notes in a private placement to raise $750m.

“Italian pharmaceutical company Recordati has purchased the rights to Cystagon (cysteamine bitartrate) in Europe from Mylan.”

Due 2028, the notes carry an interest rate of 5.2% a year and have been subscribed to by institutional investors.

Mylan has simultaneously issued 4.55% senior notes due 2028 in a private placement to raise $750m.

The placement was subscribed to by individuals outside the US.

Mylan plans to use the proceeds from the placements for repaying debt.

US-based biopharmaceutical company MannKind has completed the private placement of 14 million shares of its common stock and warrants priced at $2 a share to raise $28m.

Certain healthcare-dedicated institutional investors have subscribed to the placement.

The company plans to use the proceeds for general corporate purposes, including expenses related to production, clinical trials, research and development, sales and marketing. It will also use the funds for marketing of Afrezza and other product candidates.

H.C. Wainwright & Co was appointed as placement agent, and Greenhill & Co. was appointed as financial adviser for the transaction.